Objective:

To investigate the role of MUC6 in esophageal epithelial barrier dysfunction and its potential as a therapeutic target in reflux esophagitis (RE), highlighting its significance in improving patient outcomes.

Key Findings:

• MUC6 expression was significantly elevated in esophageal tissues of RE patients compared to non-RE patients, suggesting a potential biomarker role.
• Downregulation of MUC6 improved esophageal epithelial barrier function and reduced inflammatory response in RE, indicating therapeutic potential.
• MUC6 may play a critical role in the pathogenesis of RE and could serve as a potential biomarker for diagnosis and treatment, warranting further investigation.

Interpretation:

The findings suggest that MUC6 contributes to esophageal epithelial barrier dysfunction in RE, indicating its potential as a therapeutic target.

Limitations:

• The study involved a small sample size of 50 patients, which may limit the generalizability of the findings; larger cohort studies are needed to validate MUC6 as a biomarker and therapeutic target.
• Further research is needed to explore the mechanisms by which MUC6 influences esophageal barrier function and inflammation.

Conclusion:

Reducing MUC6 expression may enhance esophageal barrier function and suppress epithelial-mesenchymal transition, offering a promising avenue for RE treatment and potential clinical applications.